RxDoctor Payments Data

Fructuoso Irigoyen Rascon, MD

Psychiatry · McAllen, TXNPI 1750364659

Payments from drug & device makers

$2,736in general payments, 2019–2025

Across 44 payments — averaging $62.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$614
  • Johnson & Johnson$464
  • Vanda Pharmaceuticals Inc.$371
  • Otsuka America Pharmaceutical, Inc.$332
  • AbbVie$238
  • Neurocrine Biosciences, Inc.$228
  • plus $490 from 7 others

What the payments were for

  • Food & beverage$2,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,736 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$28,208
Medicare patients
93
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole37$95,416
Wellbutrin XlBupropion Hcl18$60,189
Abilify MaintenaAripiprazole15$44,943
VraylarCariprazine Hcl22$38,563
AustedoDeutetrabenazine13$36,449
TrintellixVortioxetine Hydrobromide51$28,219
CaplytaLumateperone Tosylate11$20,569
Aripiprazole174$18,910
Buspirone Hcl542$18,804
Divalproex Sodium ErDivalproex Sodium98$13,652
Lurasidone Hcl38$12,103
Quetiapine Fumarate316$10,305
LunestaEszopiclone11$9,119
Olanzapine158$7,200
Alprazolam486$7,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$332$140,35952 claims
AbbVieVraylar$238$38,56322 claims
Teva Pharmaceuticals USA, Inc.Austedo$614$36,44913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$28,21951 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$128$20,56911 claims
Johnson & JohnsonRisperdal$464$4,86811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →